IMPORTANT SAFETY INFORMATION FOR PREVNAR 13^®

• Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13^®, Prevnar^® (Pneumococcal
  7-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]), or any diphtheria toxoid-containing vaccine is a contraindication to the use of Prevnar 13^®
• Prevnar 13^® does not provide 100% protection against vaccine serotypes or protect against nonvaccine serotypes
• Immunocompromised children or children with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to active immunization
• Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including Prevnar 13^®, to infants born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination
• The most commonly reported serious adverse events were bronchiolitis (0.9%, 1.1%), gastroenteritis (0.9%, 0.9%), and pneumonia (0.9%, 0.5%) for Prevnar 13^® and Prevnar^®, respectively
• The most commonly reported solicited adverse reactions (≥20%) in US clinical trials with Prevnar 13^® were redness, swelling and tenderness at the injection site, fever, decreased appetite, irritability, increased sleep, and decreased sleep

Please see full Prescribing Information for Prevnar 13^®